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Recent molecular studies have described a number of abnormalities associated with the progression and dediﬀerentiation of
thyroid carcinoma. These distinct molecular events are often associated with speciﬁc stages of tumor development. In particular,
remarkable advances have occurred in several major biological areas of thyroid cancer, including the molecular alterations for the
lossofradioiodineavidityofthyroidcancer,thepathogenicroleoftheMAPkinaseandPI3K/Aktpathwaysandtheirrelatedgenetic
alterations, and the aberrant methylation of functionally important genes in thyroid tumorigenesis and pathogenesis. Recognition
of these features is crucial to the management of patients with thyroid cancer. Novel treatments are being designed based on our
enhanced understanding of this disease process.
1.Introduction
The incidence of thyroid cancer, the most common endo-
crine malignancy, has been rising gradually over the past
decade. The major histological types of the follicular cell-
derived thyroid cancer are papillary thyroid cancer (PTC),
follicularthyroidcancer(FTC),andanaplasticthyroidcancer
(ATC) [1–4]. Benign thyroid adenoma (BTA) is a common
endocrine tumor. On the other hand, medullary thyroid
cancer arises from the parafollicular or C cells and is not of
follicular cell origin. For that reason, it is not presented in
this paper.
Accumulating evidence indicates that follicular cell-
derived thyroid carcinomas constitute a biological contin-
uum progressing from the highly curable well-diﬀerentiated
thyroid carcinoma (WDTC) to the often fatal undiﬀerenti-
ated or anaplastic thyroid carcinoma (ATC) [5, 6]. Poorly
diﬀerentiated thyroid carcinoma (PDTC) and aggressive
variants of WDTC, such as tall cell and columnar cell,
frequently serve as intermediates in this progression model.
Clinical, epidemiologic, and pathologic evidence sup-
ports the concept of stepwise progression and dediﬀeren-
tiation [7]. For example, the gradual loss of papillary and
follicular growth patterns and the simultaneous increase in
a solid growth pattern, with increased mitoses, necrosis,
and nuclear pleomorphism, are often observed in aggressive
thyroid carcinomas [8, 9]. A majority of these tumors exhibit
residual foci of diﬀerentiated thyroid carcinoma.
There are also several diagnostic challenges that are
often encountered in the clinical management of thyroid
cancer. One is the diagnostic dilemma associated with
“indeterminate cytology” on the widely used ﬁne needle
aspiration biopsy (FNAB) in the evaluation of thyroid nod-
ules. For example, in the United States, about 300,000 cases
of thyroid nodules, which are mostly BTA, are diagnosed
annually [10]. Moreover, 20–30% of these FNAB cases show
“indeterminate” cytological ﬁndings, a pattern that has been
reported to remain essentially unchanged over the last two
decades [11, 12]. These patients currently virtually all pursue
thyroid surgery to deﬁnitely reveal the nature of the nodules
although vast majority of them will surgically prove to have
benign nodules.
Careful risk stratiﬁcation is a key step in the decision
making for appropriate surgical and medical managements
of patients with thyroid cancer. This risk evaluation is
conventionally based on clinicopathological factors, which2 Journal of Thyroid Research
are often unreliable and are mostly unavailable prior to
thyroid surgery.
Most thyroid cancer patients have an excellent outcome,
and standard treatment usually consists of total thyroidec-
tomy, often with lymph node resection, thyroid hormone
suppressive therapy, and in more advanced staged disease,
radioactive iodine (I-131) for either remnant ablation or
therapeutic treatment [13–15]. These standard therapies
are dependent on the tumor exhibiting a diﬀerentiated
phenotypesimilartonormalthyrocytesconsistingofrespon-
siveness to the growth factor TSH via the presence of
the TSH receptor and expression of the sodium-iodide
symporter (NIS) [16, 17]. Surveillance for these patients
typicallyconsistsofcombinationofanatomicalimagingsuch
as neck ultrasound [18, 19], radioiodine whole body scans,
and serum measurement of the thyroid-speciﬁc protein thy-
roglobulin with antithyroglobulin antibody levels [20, 21].
On the other hand, thyroid cancer patients with
recurrent or metastatic disease can have mortality rates
approaching 50% [22]. Dediﬀerentiation of thyroid cancer
may consist of loss of expression of the TSH receptor,
NIS, and loss of thyroglobulin production. In the process
of a tumor losing NIS expression, the clinician loses the
ability to use radioiodine for monitoring and treatment.
However, this subset of tumors frequently become visible
with 18F-ﬂuorodeoxyglucose positron emission tomography
scans (FDG-PET) [23]. Clinically, these FDG-PET positive,
noniodineavidtumorshavelimitedtreatmentoptionswhich
may include observation, additional surgery, external beam
radiation, conventional chemotherapy like the US FDA-
approved agent doxorubicin, and clinical trials.
The recent introduction of targeted therapeutic agents
that have multiple targets, including the receptor tyrosine
kinases, nonreceptor tyrosine kinases, and serine-threonine
kinases, has shown much promise in trials for thyroid cancer
patients with advanced disease [24].
The current goal of molecular medicine is to be able to
proﬁle each patient’s tumor in order to determine which
treatments will achieve the maximal response with minimal
side eﬀects. There have been signiﬁcant conceptual and
technicaladvancesinelucidatingareasoftumorbiologysuch
asgenetic and/or epigenetic regulation, buta unifying theory
for thyroid carcinogenesis is lacking. This review aims to
provide a framework to understand the rationale of how
selected research developments may segregate tumors into
diﬀerent therapeutic regimens.
2. Chromosomal Rearrangements
One of the earliest genetic changes identiﬁed in papillary
thyroid cancer was chromosomal alterations involving the
proto-oncogene RET (rearranged during transfection) [25].
The RET (rearranged during transfection) proto-oncogene
is a 21-exon gene located on the proximal long arm of
chromosome 10 that encodes a tyrosine kinase receptor. It is
involvedintheregulationofgrowth,survival,diﬀerentiation,
and migration of cells of neural crest origin. It is not
normally expressed in the follicular cell [26]. The unique
spatial proximity of translocation-prone gene loci, which
may be preferentially occurring in thyrocytes in their mitotic
interphase, favors RET gene rearrangements [27, 28]. This
may help explain why RET rearrangements are speciﬁc for
thyroid tumors [29, 30].
Although more than 10 rearrangements have been
described, RET/PTC1, RET/PTC2, and RET/PTC3 account
for most of the rearrangements found in PTC [31, 32]. In
each of these rearrangements, the upstream (5 ) component
of a “housekeeping” (or ubiquitously expressed) gene drives
the expression of the tyrosine kinase domain of RET.
ExpressionoftheRET/PTCchimericproteinsisfacilitatedby
the heterologous promoters provided by the fused genes and
results in constitutive, ligand-independent activation of RET
receptor tyrosine kinase in papillary cancer cells [33–35].
Clinically, RET/PTC variants are often found in
radiation-associated PTC. The increase in pediatric thyroid
cancers following the Chernobyl nuclear plant explosion in
1986 resulted in two groups of thyroid cancer. The ﬁrst was
an early appearing and aggressive solid variant of PTC which
contained the RET/PTC3 rearrangement while a later onset
of PTC, with a more classical phenotype and clinical course,
in the Chernobyl survivors contained RET/PTC1 [36].
Both transgenic mouse models and in vitro cellular work
have shown these fusion proteins as capable of initiating
PTC [37, 38]. RET/PTC rearrangements are less commonly
found in undiﬀerentiated thyroid cancers, suggesting that
these tumors may be managed with conventional treatment
[39]. Moreover, the utility of RET/PTC identiﬁcation from
FNA of thyroid nodules for diagnosis of PTC is beginning to
be used [40].
There is evidence to support the belief that RET/PTC
rearrangements represent early genetic changes leading to
the development of PTC [41]. In approximately 20% of
sporadic PTCs, RET/PTC rearrangements have been found
[42].Moreover,ithasbeenalsofoundinadenomasandother
benign lesions of the thyroid [43, 44]. However, since it is
present in most tumor cells, it is reasonable to consider it
speciﬁc for PTCs [45].
Several studies have shown that RET/PTC rearrangeme-
nts are associated with PTC that lacks evidence of progres-
sion to PDTC or ATC [46]. A recent study from Santoro et al.
[47] showed that less than 10% of PDTCs were positive for
RET/PTC rearrangements. They concluded that PTCs with
RET/PTC rearrangements have a relatively low potential for
progression to PDTC or ATC.
Recently, compounds have been identiﬁed that exhibit
signiﬁcant inhibitory activity on RET kinase [48]. In
particular, the recent success in the treatment of chronic
myelogenous leukemia with imatinib mesylate, an inhibitor
of constitutively activated ABL kinase, has generated con-
siderable interest in developing therapeutic protein kinase
inhibitors. There are multiple drugs in trial with activity
against RET, most notably ZD6474-Vandetanib and Bay 43-
9006-Sorafenib, but these agents also target other tyrosine
kinase receptors [49]. In particular, Sorafenib has now been
shown in two phase II clinical trials to have achieved a
partial response rate of 15 and 23% in patients [50]. Due
to Vandetanib’s ability to block RET signaling activity, it is
primarily being used for medullary thyroid cancer patients;Journal of Thyroid Research 3
however, there is an ongoing phase II trial including DTC
patients [51].
3. RAS Mutations
The RAS (an abbreviation of RAt sarcoma) family of onco-
genes regulates two important signaling pathways in thyroid
3 cancer, the mitogen-activated protein kinase/extracellular
signal-regulated kinase (RAS/Raf/MEK/ERK) and the phos-
phatidylinositol-3 kinase(PI3K)/Aktsignaling pathways.Ras
mutations occur in both benign and malignant thyroid
tumors, with variable frequency in ATCs [52].
ThreeRASgenes,H-RAS,K-RAS,andN-RAS,synthesize
a family of 21-kDa proteins that play an important role in
tumorigenesis [53]. The RAS proteins exist in two diﬀerent
forms: an inactive form that is bound to guanosine diphos-
phate (GDP) and an active form that exhibits guanosine
triphosphatase (GTPase) activity. Their function is to convey
signals originating from tyrosine kinase membrane receptors
to a cascade of mitogen-activated protein kinases (MAPKs).
This activates the transcription of target genes involved in
cell proliferation, survival, and apoptosis [54]. Oncogenic
RAS activation results from point mutations, aﬀecting the
GTP-binding domain (codons 12 or 13) in exon 1 or the
GTPase domain (codon 61) in exon 2, which ﬁx the protein
in the activated state and thus resulting in chronic stimula-
tion of downstream targets, genomic instability, additional
mutations, and malignant transformation [55]. The RAS
mutations are among the most common mutations found
in transformed cells. Mutations in all three cellular RAS
genes have been identiﬁed in benign and malignant thyroid
tumors. They seem to be common in follicular carcinoma,
PDTC, and ATC and occur less frequently in PTC [56, 57].
The role of oncogenic RAS in thyroid tumor progression is
unclear.
Some studies have shown a similar prevalence of RAS
mutations in benign and malignant thyroid neoplasms,
suggesting that RAS activation may represent an early
event [58]. Other studies have shown that RAS mutations,
speciﬁcally mutations at codon 61 of N-RAS, are involved
with tumor progression and aggressive clinical behavior
[59, 60]. Transgenic mice with thyroid-speciﬁc mutant RAS
expression develop thyroid hyperplasia and carcinoma [61].
ArecentstudybyGarcia-Rostanetal.[62]demonstratedthat
the presence of RAS mutations predicted a poor outcome for
WDTC independent of tumor stage.
Furthermore, they found that PDTC and ATC often
harbor multiple RAS mutations. These mutations probably
represent an intermediate event in the progression of thyroid
carcinoma.
4. BRAF Mutationand MAP KinaseSignaling
Pathway in Thyroid Cancer
The evolutionarily conserved mitogen-activated protein
kinase (MAPK) signaling pathway allows a cell to respond
to external stimuli such as hormones and growth factors
thatinteractwithvariousreceptors,includingtyrosinekinase
receptors like RET and G-protein-coupled receptors like the
TSH receptor. In thyroid cancer, RET/PTC rearrangement
is a common activator of the MAP kinase pathway [63].
ActivatingRasmutations,whichcanactivatetheMAPkinase
pathway, are also common in thyroid cancer [64].
BRAF mutation is a major cause of aberrant activation
of the MAP kinase pathway in human cancers [65]. Among
the three known Raf kinases, A-Raf, B-Raf (BRAF), and C-
Raf, BRAF is the most potent activator of the MAP kinase
pathway [66]. The T1799A point BRAF mutation accounts
for more than 90% of the more than 40 mutations identiﬁed
in the BRAF gene [63]. This mutation causes a V600E amino
acid change in the BRAF protein, resulting in constitutive
and oncogenic activation of the BRAF kinase [67, 68].
Discovery and characterization of the T1799A BRAF
mutationinthyroidcancerrepresentoneofthemostexciting
advances in the molecular biology of thyroid cancer in
recent years [69, 70]. In fact, this mutation is the most
common known genetic alteration in thyroid cancer. A few
other activated BRAF mutants are only rarely found in
thyroidcancer.TheseincludetheBRAFK601E[71],AKAP9-
BRAF [66], BRAF V600E+K601del [72, 73], BRAF V599ins
[74], and V600D+FGLAT601-605ins, which result from an
insertion of 18 nucleotides at nucleotide T1799 [73]. Thus,
the T1799A mutation is the most common and virtually the
only BRAF mutation identiﬁed in thyroid cancer, commonly
referred to as “BRAF mutation.”
Previous studies have showed that BRAF mutation was
not a germline mutation in familial nonmedullary thyroid
cancers [75, 76] and, as a somatic genetic alteration, occurs
exclusively in PTC and PTC-derived ATC, with an average
prevalence of about 45% in the former and 25% in the latter;
it does not occur in FTC or other types of thyroid tumors
[66, 68]. Transgenic mouse model [73] with cell line and
xenograft tumor studies [77, 78] demonstrated the tumori-
genic ability of the BRAF mutation and its requirement to
maintain cancer cell growth and proliferation.
Numerous clinical studies demonstrated an association
of BRAF mutation with aggressive clinicopathological out-
comes, including tumor invasion, metastasis, and recurrence
of PTC [66, 68]. Moreover, it was demonstrated an interest-
ing association of BRAF mutation with loss of radioiodine
avidity in recurrent PTC and its failure to be cured [79]. This
is consistent with research data of BRAF mutant-promoted
silencing of thyroid iodide-handling genes and the reversal
of this process by silencing the expression of BRAF mutant
in thyroid cells. Additionally, several studies demonstrated a
close association of BRAF mutation with dediﬀerentiation of
PTC as reﬂected by decreased expression of thyroid-speciﬁc
genes in PTC, including NIS [80, 81], TPO [77–84], pendrin
[84], and Tg [80]. Therefore, BRAF mutation is a novel
powerful molecular prognostic marker for poorer prognosis
of thyroid cancer.
5.PI3K/Akt SignalingPathway
inThyroid Cancer
Like the MAP kinase pathway, the phosphatidylinositol-
3 kinase (PI3K)/Akt signaling pathway (PI3K pathway)
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proliferation, and survival, and in human tumorigenesis
[85, 86]. Among the several classes of PI3Ks, class I is
the best characterized and is composed of heterodimers
of a regulatory subunit, particularly p85, and one of the
several p110 catalytic subunits. The α-type (PIK3CA) and
β-type (PIK3CB) p110 subunits are widely expressed in
diﬀerent tissues, whereas other types of p110 subunits are
only expressed in limited tissues.
There are three types of Akts: Akt-1, Akt-2, and Akt-3.
Activated Akt phosphorylates downstream protein eﬀec-
tors and ampliﬁes the signaling cascade, promoting cell
proliferation and inhibiting apoptosis. Signaling of the
PI3K/Akt pathway is antagonized by the tumor suppressor
gene PTEN product, PTEN, which is a phosphatase that
dephosphorylates PIP3, hence terminating the signaling of
the PI3K/Akt pathway [87].
Previous studies showed common activation of the PI3K
signaling in thyroid cancers [88]. The three isoforms of Akt,
Akt-1, and Akt-2 were the most abundant and important in
thyroid cancer. It was reported that genomic copy gain and
ampliﬁcation of the PIK3CA occur in thyroid tumors, par-
ticularly FTC and ATC [89–91].Moreover,PIK3CAmutation
is particularly common in ATC and is relatively uncommon
but can occur in diﬀerentiated thyroid cancer [88–91]. A
number of genetic alterations in the PI3K pathway, including
PIKCA mutation and ampliﬁcation, Ras mutation, and
PTEN mutation are found in a relatively high prevalence,
particularly in FTC and ATC tumors [90, 91]. Coexistence
of some of these genetic alterations and their coexistence
with BRAF mutation were more frequently seen in aggressive
thyroid cancers, particularly ATC [90]. Interestingly, genetic
alterationsthatcouldactivateboththeMAPkinaseandPI3K
pathways were found in most (81%) ATCs.
These data provide the strongest genetic evidence for an
extensive role of dual involvement of the MAP kinase and
PI3K pathways in the pathogenesis of ATC, supporting a
recent hypothesis that targeting multiple signaling pathways,
particularly the MAP kinase and PI3K/Akt pathways, may
be an eﬀective and necessary therapeutic strategy for thyroid
cancer.
6. PAX8-PPARγ Rearrangement
The PAX8 gene encodes a transcription factor essential for
the genesis of thyroid follicular cell lineages and regula-
tion of thyroid-speciﬁc gene expression. The peroxisome
proliferator-activated receptor γ (PPARγ) is a member of the
nuclear hormone receptor superfamily that includes thyroid
hormone,retinoicacid,andandrogenandestrogenreceptors
[92]. The PAX8-PPARγ rearrangement leads to in-frame
f u s i o no fe x o n7 ,8 ,o r9o fP A X 8o n2 q 1 3w i t he x o n1o f
PPARγ on 3p25 [93].
The exact mechanism by which this rearrangement
imparts a carcinogenic phenotype is not fully understood.
It appears as though the PAX8-PPARγ chimeric protein
inactivates the wild-type PPARγ,w h i c hi sap u t a t i v et u m o r
suppressor [93, 94].
AswithRASmutations,PAX8-PPARγ rearrangementhas
alsobeenshowntobeinvolvedinthedevelopmentofthyroid
follicular carcinoma. The PAX8-PPARγ rearrangement is
f o u n di nf o l l i c u l a rt h y r o i dc a r c i n o m aa n di nt h ef o l l i c u l a r
variant of PTC, where it occurs in approximately 33% of all
tumors [95, 96]. The rearrangement has also been shown
to occur in follicular adenomas and is not speciﬁc for
carcinoma [95].
The role of this rearrangement in the progression and
dediﬀerentiation of follicular thyroid cancer to PDTC and
ATC has not been well deﬁned.
7. p53 Inactivation
The p53 gene encodes a nuclear transcription factor that
plays a central role in the regulation of cell cycle, DNA repair,
and apoptosis [97]. As the guardian of the genome, p53
is overexpressed after cellular exposure to DNA-damaging
agents and causes transient cell cycle arrest, presumably to
allow for DNA repair [98].
However, if the damage is severe, it initiates apoptosis to
prevent replication of the ﬂawed cell. Cells with impaired
p53 function are likely to accumulate genetic damage and
are at a selective advantage for clonal expansion. Alterations
in the p53 tumor suppressor gene by inactivating point
mutations, usually involving exons 5–8, or by deletion result
in progressive genome destabilization, additional mutations,
and propagation of malignant clones. This represents the
most frequent genetic damage in human cancer, usually
occurring as a late tumorigenic event.
Among thyroid tumors, p53 mutations are generally
restricted to PDTC and ATC [99, 100]. Point mutations of
p53occurinapproximately60%ofATCandin25%ofPDTC
[99–101] .M o r e o v e r ,i nt u m o r sw i t hb o t hw e l l - d i ﬀerentiated
andanaplasticcomponents,p53mutationswerepresentonly
in the anaplastic component [102–104]. These ﬁndings are
consistent with the hypothesis that p53 inactivation likely
serves as a second hit, triggering tumor dediﬀerentiation and
progression to PDTC and ATC.
Experimental studies have shown that loss of p53 results
in progressive dediﬀerentiation of thyroid tumors. Trans-
genic mice with thyroid-speciﬁc RET/PTC rearrangements
developed PTC, but when crossed with p53−/− mice, the
progenysuccumbedtorapidlygrowingPDTCandATC[105,
106]. Conversely, the recovery of wild-type p53 in cultured
ATC cells resulted in the re-expression of thyroid-speciﬁc
genes and the reability to respond to thyroid-stimulating
hormone [107, 108].
It is unlikely that p53 mutation is an initiating event in
PDTC or ATC; it is likely a late event that contributes to the
evolution of the transformed phenotype.
8. Epigenetic Regulation inThyroid Cancer
Recognizing that DNA is associated with histone proteins to
form a condensed structure known as chromatin, research is
now investigating how modiﬁcations in chromatin structure
may contribute to carcinogenesis. Epigenetic modiﬁcations
refer to heritable alterations of the DNA structure, histones,
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expression [109]. Epigenetic changes have been described in
thyroid cancer, most notably the altered DNA methylation
patterns in the CpG islands of promoters of genes important
in normal thyrocyte function such as the sodium-iodide
symporter and the TSH receptor [110, 111]. Increased
promotermethylation by DNAmethyltransferases(DNMTs)
leads to gene silencing and further dediﬀerentiation of
the thyroid tumor. DNMT inhibitors such as 5 -aza-
deoxycytidine are being evaluated as “rediﬀerentiation”
agents, thereby allowing tumors to again become more
responsivetoconventionaltherapysuchasradioactiveiodine
[112]. Identiﬁcation of speciﬁc methylation patterns may
also allow stratifying tumors that may no longer be respon-
sive to thyroid hormone suppressive therapy and I-131.
Research on how posttranslational modiﬁcation of his-
tones may inﬂuence cancer has recently seen tremendous
growth. The nucleosome, or basic structural unit of chro-
matin, consists of 147bp of DNA wrapped around an
octamer of four core histone proteins (H2A, H2B, H3,
and H4) [113]. Histone modiﬁcations include methylation,
acetylation, phosphorylation, and ubiquitination and may
act in concert with DNA promoter methylation to modulate
genesilencing[114].Epigeneticdrugtargetsmayplayamore
central role in cancer treatment in the future.
9. Conclusions
Remarkable advances have occurred in recent years in
understanding the molecular biology of thyroid cancer.
This is reﬂected in several major biological areas of
thyroid cancer, including the molecular alterations for the
loss of radioiodine avidity of thyroid cancer, the pathogenic
role of the MAP kinase and PI3K/Akt pathways and their
related genetic alterations, and the aberrant methylation of
functionally important genes in thyroid tumorigenesis and
pathogenesis. These exciting advances in molecular biology
shinegreatpromisesonthedevelopmentofnovelmolecular-
based strategies to eﬀectively tackle these diagnostic, prog-
nostic, and therapeutic obstacles of thyroid cancer.
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